Sublingual drug administration involves placing medications under the tongue for absorption through the oral mucosa directly into the bloodstream. This route offers rapid absorption and bypasses first-pass metabolism, making it particularly valuable for certain medications requiring quick onset or those that would be degraded by digestive processes.
Forms of Sublingual Medications
- Tablets: Fast-dissolving tablets designed for under-tongue placement
- Films: Thin strips that dissolve rapidly
- Sprays: Liquid medications in spray form
- Drops: Liquid preparations
- Powders: Quick-dissolving powder formulations
Advantages
- Rapid absorption and onset
- Bypasses first-pass metabolism
- Good blood supply to absorption area
- Convenient administration
- No water needed
- Useful in emergencies
- Discreet administration possible
- Good for patients with swallowing difficulties
Disadvantages
- Limited drug options
- Small absorption area
- Short contact time
- Taste considerations
- Salivation effects
- Limited dose size
- May require frequent dosing
- Some technical skill needed
Best Practices
- Clean, dry mouth before administration
- Correct placement under tongue
- Avoid swallowing medication
- Allow complete dissolution
- No eating/drinking during absorption
- Proper timing between doses
- Check for oral conditions
- Follow specific product instructions
Special Considerations
- Oral hygiene status
- Salivary flow rates
- Mouth dryness
- Speaking limitations during administration
- Concurrent medications
- Storage requirements
- Cost factors
- Patient technique verification
Sublingual Absorption and Formulation Requirements
The sublingual mucosa is highly vascularized, with blood flow of 1–3 mL/min/cm², enabling rapid drug absorption directly into the systemic circulation and complete avoidance of hepatic first-pass metabolism. The formulation must dissolve quickly in the small volume of saliva (0.5–1 mL) under the tongue — disintegrants (e.g., croscarmellose sodium, sodium starch glycolate) and water-soluble excipients (e.g., mannitol, sorbitol) facilitate rapid dissolution. The drug must have sufficient lipophilicity to cross the mucosal membrane (log P 1–3) and be potent enough for the small dose range (typically < 20 mg per dose). Nitroglycerin sublingual tablets (0.3–0.6 mg) provide relief from angina pectoris within 2–3 minutes by directly dilating coronary arteries — the tablet should be placed under the tongue and allowed to dissolve completely without swallowing. Buprenorphine sublingual tablets (2–8 mg) are used for opioid addiction treatment (MAT); sublingual bioavailability is 30–50% compared to <10% if swallowed. The patient should place the tablet under the tongue, avoid eating, drinking, or talking for 5–10 minutes while it dissolves, and not swallow saliva until dissolution is complete. Salivation increases drug loss to the gastrointestinal tract — patients should tilt their head slightly forward to minimize saliva flow to the pharynx. Contraindications include oral mucositis (chemotherapy), xerostomia (dry mouth, Sjögren’s syndrome), and concurrent use of medications that reduce mucosal blood flow.
Conclusion
Sublingual drug administration offers unique advantages for specific medications requiring rapid onset or bypass of first-pass metabolism. Success depends on proper technique, patient education, and attention to factors affecting absorption through the oral mucosa.
